enGenes presents high-titer continuous plasmid DNA production solution to ISCT Dublin

Vienna, Austria: – End-to-end bioprocessing specialist CDMO enGenes Biotech will bring details of its groundbreaking iCAP plasmid DNA continuous production platform to the upcoming annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Dublin.

enGenes CEO Dr Jürgen Mairhofer will lead the company’s presence at the conference, which has become recognized as one of the world’s leading events in the field of Cell and Gene Therapy (CGT) Translation, attracting more than 3,000 delegates from at least 60 countries.

iCAP continuous pDNA project

Dr. Mairhofer will provide an oral ‘elevator pitch’ summary of the enGenes poster submitted to the ISCT conference “iCAP – An Integrated, Continuous and Automated Platform for High-Titer Plasmid DNA Production.”

This will summarise enGenes Biotech’s progress in pioneering an advanced, high-yield, and low-consumption end-to-end continuous pDNA manufacturing platform that leverages its proprietary enGenes-eXcess technology. This optimizes upstream and downstream processes to enable significant yield improvements for precise and reproducible production of high-quality plasmid DNA in a cost-effective manner.

Game changer for vaccines and CGT

The poster shows how high-titer plasmid DNA production can be a significant game-changer for gene therapy and vaccine development in radically reducing COG outcomes.

Dr Mairhofer commented: “We are very much looking forward to attending ISCT 2026 in Dublin to hear the latest progress in this exciting field.”

“This is an excellent opportunity to spread the good news about our expanded pDNA capabilities, especially since every successful C&GT development needs high-quality pDNA, manufactured with reproducible and scalable quality even at an early stage.”

CGT project partner

“We can show how enGenes is the perfect partner for advanced vaccine and gene therapy projects, since we can now provide R&D-grade high-quality plasmid DNA much faster and with demonstrated ability to transfer these processes within cGMP protocols,” Jürgen Mairhofer noted.

“Now with iCAP we have developed a unique, fully end-to-end continuous pDNA manufacturing process that can run uninterrupted over more than 30 days with a S-T-Y of 1 g/L/d at liter scale with a very small footprint. This represents a new future for C&GT applications where such a process could be coupled to a continuous viral particle manufacturing process,” he explained.

“All this comes together to make pDNA far more viable and cost-effective as a raw material than it is currently,” Dr Mairhofer added.

To discuss specific project needs, Dr Mairhofer can be contacted to book face-to-face meetings in Dublin via the conference networking platform (see Resources).

About enGenes Biotech

With more than a decade of proven expertise, enGenes Biotech develops bioprocesses that consistently outperform conventional approaches. The company’s proprietary technology platforms deliver higher yields, faster timelines, and superior scalability for recombinant proteins, peptides and plasmid DNA production in E. coli. These directly translate into reduced production costs and accelerated market entry. From early concept to industrial process, they enable pharmaceutical, diagnostic and industrial applications to achieve results that set new industry benchmarks at a fraction of the cost.

enGenes Biotech’s expertise spans every step of the biomanufacturing lifecycle: molecular biology, upstream and downstream processing, analytics, process scale-up, product development, and market entry. It can deliver tailored solutions that reduce costs, advance sustainable innovation, and improve customers’ competitive position in the global marketplace.

The company offers development and manufacturing services for recombinant proteins, peptides, and plasmid DNA tailored to the needs of pharmaceutical and industrial biotech companies. Their integrated service portfolio ensures efficiency, quality, and speed in tackling even the toughest challenges. In addition, they are building a portfolio of high-quality and cost-effective products, with an initial focus on endonucleases and protein A-based affinity ligands.

Find out more at: https://www.engenes.cc

About ISCT 2026

The annual meeting of the International Society for Cell & Gene Therapy (ISCT) is now recognized as one of the world’s leading events in the field of Cell and Gene Therapy (CGT) Translation.

The meeting regularly attracts more than 3,000 delegates from at least 60 countries, representing key stakeholders spanning the full CGT development pathway from early research through clinical development to commercialization and patient access, including clinicians, researchers, manufacturing professionals, and regulatory authorities. The Meeting also brings together hospital and treatment center teams, health economists, investors, and technology innovators, data and AI experts.

ISCT 2026 is a four-day event opening May 6 at the Dublin Convention Center and will feature more than 250 speakers, along with more than 7000 individual partnering meetings already booked.

The event is organised by ISCT with further information at: https://www.isctglobal.org/annual-meeting/home.

Resources

Book a meeting with Jürgen Mairhofer in Dubln via ISCT Partnering Platform.
Click on enGenes Biotech Technologies to learn more about the eXcess platform.